The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Clinical Oncology Next Generation Sequencing Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The clinical oncology next generation sequencing market size has expanded significantly in recent years. It is anticipated to increase from $0.58 billion in 2025 to $0.66 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.3%. The market’s past growth can be attributed to the broadening of cancer genomics research, the greater availability of sequencing platforms, an increase in oncology clinical trials, the rising acceptance of molecular diagnostics, and the reduction in sequencing costs.
The clinical oncology next generation sequencing market size is projected to expand significantly in the coming years, reaching $1.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.1%. This expansion during the forecast period is primarily driven by factors such as the increasing demand for precision oncology, rising investments in genomic medicine, the expansion of hospital-based sequencing laboratories, the growing use of targeted cancer therapies, and continuous advancements in sequencing technologies. Furthermore, major trends anticipated within this period include a greater adoption of NGS-based oncology diagnostics, the rising use of companion diagnostic applications, growing integration of bioinformatics and data analytics, the expansion of personalized cancer treatment approaches, and an enhanced focus on rare mutation detection.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp
What Key Drivers Are Influencing The Growth Of The Clinical Oncology Next Generation Sequencing Market?
The increasing incidence of cancer is anticipated to stimulate the expansion of the clinical oncology next-generation sequencing market moving forward. Cancer refers to a group of illnesses characterized by the uncontrolled division and spread of abnormal cells throughout the body. The growing occurrence of cancer is primarily linked to an aging population, as the risk of cancer significantly elevates with age. NGS is employed to identify both new and rare mutations within cancer, offering a deeper insight into the molecular foundations of individual tumors. For example, in February 2024, the World Health Organization, a Switzerland-based public health agency of United Nations, projected over 35 million new cancer cases by 2050, which represents a 77% increase compared to the estimated 20 million cases reported in 2022. Thus, the escalating prevalence of cancer is a key factor driving the growth of the clinical oncology next-generation sequencing market.
What Major Segment Divisions Exist Within The Clinical Oncology Next Generation Sequencing Market?
The clinical oncology next generation sequencing market covered in this report is segmented –
1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories
Subsegments:
1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies
2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies
3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies
4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies
5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies
6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies
7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies
How Are Trends Shaping The Direction Of The Clinical Oncology Next Generation Sequencing Market?
Major companies operating in the clinical oncology next-generation sequencing (NGS) market are emphasizing technological advancements, such as incorporating software accelerators designed to significantly reduce the time and cost involved in second-level NGS analysis, thereby enabling laboratories to deliver results faster while minimizing computational resource requirements. These accelerator technologies support comprehensive genomic profiling and enhance the accessibility of high-throughput cancer panels for both large centralized laboratories and decentralized diagnostic settings. For example, in January 2024, QIAGEN Digital Insights, a Germany-based bioinformatics company, launched an upgraded version of its CLC Genomics Workbench Premium featuring LightSpeed technology, which now supports somatic cancer secondary analysis. The LightSpeed accelerator is capable of analyzing a 275-gene cancer panel at 3377× coverage in just 6 minutes, costing less than US$ 0.72 per test in standard cloud environments. LightSpeed is optimized to provide high speed, accuracy, reduced power consumption, and eliminates the need for new hardware or additional licenses beyond the existing CLC platform.
Which Companies Are Leading Innovation In The Clinical Oncology Next Generation Sequencing Market?
Major companies operating in the clinical oncology next generation sequencing market are Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.
Read the full clinical oncology next generation sequencing market report here:
Which Region Is Expected To Register The Fastest Growth In The Clinical Oncology Next Generation Sequencing Market?
North America was the largest region in the clinical oncology next-generation sequencing market in 2025. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Clinical Oncology Next Generation Sequencing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp
Browse Through More Reports Similar to the Global Clinical Oncology Next Generation Sequencing Market 2026, By The Business Research Company
Clinical Chemistry Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-chemistry-global-market-report
Dental Diagnostic Imaging Devices And Equipment Market Report 2026
Biochemistry Analyzer Market Report 2026
https://www.thebusinessresearchcompany.com/report/biochemistry-analyzer-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model